Delivery Order SPE2DB22D9239-SPE2DB25FDJ99

Award Date 6/11/25
Potential Completion Date 6/12/25
Potential Value $43K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $43,113.50 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product, to support the medical supply needs of military health facilities. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $12,934.05 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product, to support the medical supply needs of military health facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a prescription medication, with a performance period ending on June 4, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $33,923.76, is for the delivery of XTANDI 40 MG CAPSULE 120S over the period of September 10, 2024 to September 10, 2024. DMS Pharmaceutical Group Inc. holds a larger single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 order is for the delivery of XTANDI 40 MG CAPSULE 120S, with a completion date of May 20, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This single-award...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 firm fixed-price contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a branded pharmaceutical product. The order has a completion date of June 14, 2024. DMS Pharmaceutical Group holds a larger, single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the SPE2DB program. The $25,868.10 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, with a performance period ending on September 18, 2024. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,311.35 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product, to support the medical supply needs of military health facilities. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract has a ceiling value of $43,113.50 and covers the supply of XTANDI 40 MG CAPSULE 120S, a pharmaceutical product, with a period of performance through March 25, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of prescription drugs, over-the-counter...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $76,753.74 contract is for the delivery of 120 capsules of the prescription drug XTANDI 40 MG. The award has an ultimate completion date of May 19, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB25FDJ99
    Delivery Order

This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $43,113.50 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a pharmaceutical product, with a completion date of June 12, 2025.

DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories.

Generated 9/10/25, 9:54 AM